ライフサイエンスコーパス: tranexamic acid

1 Thrombolysis was suppressed with tranexamic acid.

2 less likely to have DWIHLs if they received tranexamic acid.

3 ith patients who did not receive prehospital tranexamic acid.

4 arding effectiveness of hormonal therapy and tranexamic acid.

5 in addition to ratio driven transfusion and tranexamic acid.

6 more likely to have DWIHLs if they received tranexamic acid.

7 ty and low cost associated with oxytocin and tranexamic acid.

8 eficient mice or wild-type mice treated with tranexamic acid.

9 understanding of the mechanism of action of tranexamic acid.

10 ected after hemostatic resuscitation without tranexamic acid.

11 the most-widely used antifibrinolytic agent, tranexamic acid.

12 tranexamic acid (1 g) bolus and in-hospital tranexamic acid (1 g) 8-hour infusion (bolus maintenance

13 iated within 2 hours of TBI: out-of-hospital tranexamic acid (1 g) bolus and in-hospital tranexamic a

14 red prophylactic uterotonic agent and either tranexamic acid (1 g) or placebo.

15 Tranexamic acid (1-g bolus followed by 1-g infusion over

16 izumab 1% (4 mg/d), estriol 0.1% (0.4 mg/d), tranexamic acid 10% (40 mg/d), or placebo (0.9% saline).

17 F, 40 IU/kg over 5-10 min on day 1, and oral tranexamic acid 1300 mg three times daily on days 1-5, t

18 use mortality was significantly reduced with tranexamic acid (1463 [14.5%] tranexamic acid group vs 1

19 and total estimated blood loss over 7 days (tranexamic acid, 1504.0 mL; placebo, 1551.2 mL; P = .38)

20 tranexamic acid/cryoprecipitate (11.6%) and tranexamic acid (18.2%) groups compared with the cryopre

21 oic acid (-184 mL; 95% CI, -256 to -112) and tranexamic acid (-195 mL; 95% CI, -286 to -105).

22 maintenance group; n = 312), out-of-hospital tranexamic acid (2 g) bolus and in-hospital placebo 8-ho

23 horter than without treatment (45 h) or with tranexamic acid (38 h).

24 .03; 95% confidence interval, 0.80-1.33) nor tranexamic acid (65 deaths among 442 patients [14.7%]; a

25 Measured intraoperative blood loss (tranexamic acid, 817.3 mL; placebo, 836.7 mL; P = .75) a

26 1295 patients], aminocaproic acid [883], and tranexamic acid [822]) as compared with no agent (1374 p

27 Combining the tranexamic acid-9-anthrylalanine affinity-modifying grou

28 tion revealed that (68)Ga-HTK03041 bearing a tranexamic acid-9-anthrylalanine affinity-modifying grou

29 tion revealed that (68)Ga-HTK03041 bearing a tranexamic acid-9-anthrylalanine affinity-modifying grou

30 ved on average 430 mL crystalloid fluids and tranexamic acid (90%).

31 en were as effective at stabilizing clots as tranexamic acid, a clinical antifibrinolytic, and in a p

32 Tranexamic acid, a hemostatic agent that is under invest

33 k for trauma-induced coagulopathy to receive tranexamic acid (administered intravenously as a bolus d

34 ials and observational studies investigating tranexamic acid administration compared with no treatmen

35 This study found that prehospital tranexamic acid administration was associated with incre

36 with moderate to severe TBI, out-of-hospital tranexamic acid administration within 2 hours of injury

37 rt delay in treatment reduces the benefit of tranexamic acid administration.

38 atment of AD mice with the plasmin inhibitor tranexamic acid aggravated pathology, whereas removal of

39 ologic inhibition of plasmin activation with tranexamic acid also delayed disease onset.

40 cologic inhibitor of plasminogen activation, tranexamic acid, also delays the onset of neuroinflammat

41 ient mice and in wild-type mice treated with tranexamic acid, an inhibitor of plasminogen activation.

42 10 096 patients were allocated to tranexamic acid and 10 115 to placebo, of whom 10 060 an

43 10,096 patients were allocated to tranexamic acid and 10,115 to placebo, of whom 10,060 an

44 pants, 96 (43.8%) were randomized to receive tranexamic acid and 123 (56.2%) were randomized to recei

45 the trial (17 received recombinant VWF then tranexamic acid and 19 received tranexamic acid then rec

46 The combined tranexamic acid and cryoprecipitate effect vs. neither i

47 Tranexamic acid and cryoprecipitate were independently a

48 -Pg contributed to cell adhesion inasmuch as tranexamic acid and epsilon-aminocaproic acid inhibited

49 ivery occurred in 0.4% of women who received tranexamic acid and in 0.1% of women who received placeb

50 iation between prehospital administration of tranexamic acid and mortality was found across the entir

51 ficiencies seen in AFE alongside the role of tranexamic acid and other coagulopathy management strate

52 ignificant difference was identified between tranexamic acid and placebo groups with regard to thromb

53 -day and 6-week mortality was similar in the tranexamic acid and placebo groups.

54 apies (pdC1-INH or icatibant), 15% were with tranexamic acid, and 35% were not treated.

55 these patients, 661 were assigned to receive tranexamic acid, and 646 were assigned to receive placeb

56 ) for acute swelling attacks and progestins, tranexamic acid, and danazol for the prevention of attac

57 the medicinal products (C1-INH concentrate, tranexamic acid, and danazol) administered for STP.

58 ts; n = 18 epsilon aminocaproic acid, n = 35 tranexamic acid, and n = 1 both).

59 of coagulation, immediate administration of tranexamic acid, and prioritization of surgical or radio

60 ion of PAI-1 with PAI-039 and stimulation by tranexamic acid, and we confirmed our results in PAI-1-d

61 antihistamines, pentoxifylline, doxepin, and tranexamic acid are not effective in most patients with

62 ve generic medications aminocaproic acid and tranexamic acid are safe alternatives.

63 sive alternatives (ie, aminocaproic acid and tranexamic acid) are available.

64 She was treated with tranexamic acid as a long-term prophylactic.

65 ical community by increasing awareness about tranexamic acid-associated seizures and by translating s

66 o the potential causes of and treatments for tranexamic acid-associated seizures.

67 Prophylactic use of tranexamic acid at the time of cesarean delivery has bee

68 The tranexamic acid biocompatible polymer microneedle used i

69 Tranexamic acid can reduce bleeding in patients undergoi

70 However, many clinicians are unaware that tranexamic acid causes seizures.

71 The results of the tranexamic acid comparison are reported here.

72 e inhibitors of plasmin have been developed: tranexamic acid conjugates targeting the S1 pocket and p

73 ll requirements, mortality was lowest in the tranexamic acid/cryoprecipitate (11.6%) and tranexamic a

74 ared with the cryoprecipitate (21.4%) and no tranexamic acid/cryoprecipitate (23.6%) groups.

75 nexamic acid (mean [SD], 23.0 [19.2]) and no tranexamic acid/cryoprecipitate (mean [SD], 21.2 [18.5])

76 cryoprecipitate (mean [SD], 28.3 [15.7]) and tranexamic acid/cryoprecipitate (mean [SD], 26 [14.9]) g

77 c acid (n = 148), cryoprecipitate (n = 168), tranexamic acid/cryoprecipitate (n = 258), and no tranex

78 xamic acid/cryoprecipitate (n = 258), and no tranexamic acid/cryoprecipitate (n = 758).

79 studies, inhibition of plasmin in mice with tranexamic acid delayed up-regulation of proinflammatory

80 r resection for a cancer-related indication, tranexamic acid did not reduce bleeding or blood transfu

81 Extended-use high-dose IV tranexamic acid did not reduce mortality (relative risk,

82 Low-dose IV/enteral tranexamic acid did not reduce mortality (relative risk,

83 Extended-use high-dose IV tranexamic acid does not improve mortality or bleeding o

84 Prophylactic use of tranexamic acid during cesarean delivery did not lead to

85 Administration of tranexamic acid during prehospital treatment.

86 ation, a levonorgestrel intrauterine system, tranexamic acid (during menstrual flow), high-dose proge

87 The approved antifibrinolytic agents such as tranexamic acid, epsilon-aminocaproic acid, 4-aminomethy

88 Participants receiving tranexamic acid experienced significantly more complicat

89 rauma systems, prehospital administration of tranexamic acid followed by an infusion over 8 hours did

90 assurance for ongoing and future trials that tranexamic acid for acute ICH is unlikely to induce cere

91 articipants with ICH enrolled in the TICH-2 (Tranexamic Acid for Hyperacute Primary Intracerebral Hae

92 eline noncontrast CT scans obtained from the Tranexamic Acid for Hyperacute Primary Intracerebral Hae

93 uble-blind, placebo-controlled, phase 3 RCT (Tranexamic Acid for Hyperacute Primary Intracerebral Hem

94 tive cohort study was based on data from the Tranexamic Acid for Preventing Postpartum Hemorrhage aft

95 We aimed to compare recombinant VWF with tranexamic acid for reducing heavy menstrual bleeding in

96 er discontinuing eOC (16 women), 93.8% under tranexamic acid (four women), and 100% under danazol (th

97 r injury, 113 of 653 patients (17.3%) in the tranexamic acid group and 139 of 637 (21.8%) in the plac

98 ed in 16.3% of participants (n = 101) in the tranexamic acid group and 14.5% (n = 91) in the placebo

99 6 months, 123 of 648 patients (19.0%) in the tranexamic acid group and 144 of 629 (22.9%) in the plac

100 ble outcomes data; 2311 were assigned to the tranexamic acid group and 2320 to the placebo group.

101 d) was seen in 11/222 (4.9%) patients in the tranexamic acid group and 27/225 (1212.0%) patients in t

102 5 was seen in 19/300 (6.3%) patients in the tranexamic acid group and 40/300 (13.3%) patients in the

103 cipants underwent randomization (5529 to the tranexamic acid group and 5471 to the placebo group); sc

104 fused during hospitalization was 4331 in the tranexamic acid group and 7994 in the placebo group (P<0

105 occurred in 16.1% of the participants in the tranexamic acid group and in 18.0% of those in the place

106 tion occurred in 1.4% of the patients in the tranexamic acid group and in 2.8% of the patients in the

107 ed in 201 of 5525 participants (3.6%) in the tranexamic acid group and in 233 of 5470 (4.3%) in the p

108 curred in 307 of 572 patients (53.7%) in the tranexamic acid group and in 299 of 559 (53.5%) in the p

109 vent occurred in 386 patients (16.7%) in the tranexamic acid group and in 420 patients (18.1%) in the

110 occurred in 556 of 2086 women (26.7%) in the tranexamic acid group and in 653 of 2067 (31.6%) in the

111 occurred in 7.3% of the participants in the tranexamic acid group and in 8.0% of those in the placeb

112 There was no increase for the tranexamic acid group compared with the placebo group in

113 lic events: 50 (0.2%) of 26 571 women in the tranexamic acid group had fatal or non-fatal thromboembo

114 The tranexamic acid group received 1 g in 100-mL intravenous

115 curred in 178 (0.65%) of 27 300 women in the tranexamic acid group versus 230 (0.85%) of 27 093 women

116 y reduced with tranexamic acid (1463 [14.5%] tranexamic acid group vs 1613 [16.0%] placebo group; rel

117 h due to bleeding (198/3747 [5.3%] events in tranexamic acid group vs 286/3704 [7.7%] in placebo grou

118 isability or good recovery]) in the combined tranexamic acid group vs the placebo group.

119 e estriol group, 7.5 (IQR, 3.0-11.0) for the tranexamic acid group, and 8.0 (IQR, 3.0-14.0) for the p

120 y outcome occurred in 65% of patients in the tranexamic acid groups vs 62% in the placebo group (diff

121 t difference in 28-day mortality between the tranexamic acid groups vs the placebo group (14% vs 17%;

122 d, for >40 years, the antifibrinolytic agent tranexamic acid has been administered for its serendipit

123 Prophylactic administration of tranexamic acid has been associated with reduced postpar

124 ytocin, ergot alkaloids, prostaglandins, and tranexamic acid, have been used prophylactically to prev

125 0 138 patients from two randomised trials of tranexamic acid in acute severe bleeding (traumatic and

126 Although we do not recommend the use of tranexamic acid in all women giving birth, consideration

127 tranexamic acid, prompting a reappraisal for tranexamic acid in gastrointestinal bleeding.

128 by calculating the diffusion coefficient of tranexamic acid in interstitial fluid (plasma).

129 gest that recombinant VWF is not superior to tranexamic acid in reducing heavy menstrual bleeding in

130 independently add to the survival benefit of tranexamic acid in the seriously injured requiring trans

131 y was to evaluate the efficacy and safety of tranexamic acid in the treatment of acute UGIB in patien

132 ndomised trials that assessed the effects of tranexamic acid in women giving birth.

133 d controlled trials to assess the effects of tranexamic acid in women giving birth.

134 In contrast, inhibition of fibrinolysis with tranexamic acid increased lesion volume by 25% compared

135 Whether prehospital administration of tranexamic acid increases the likelihood of survival wit

136 We found no evidence that tranexamic acid increases the risk of thrombosis.

137 Both epsilon-aminocaproic acid and tranexamic acid inhibit clot dissolution.

138 Tranexamic acid inhibited ICH expansion in uPA(-/-)mice

139 The Haemorrhage Alleviation with Tranexamic Acid-Intestinal System trial evaluated extend

140 ment bundle (ie, uterine massage, oxytocics, tranexamic acid, intravenous fluids, examination and esc

141 treatments (uterine massage, oxytocic drugs, tranexamic acid, intravenous fluids, examination and esc

142 treatments (uterine massage, oxytocic drugs, tranexamic acid, intravenous fluids, examination, and es

143 Tranexamic acid is a novel drug for treating melasma tha

144 Tranexamic acid is a recommended treatment for women wit

145 trauma patients admitted late after injury, tranexamic acid is less effective and could be harmful.

146 Tranexamic acid is proposed as a treatment for gastroint

147 Because tranexamic acid is thought to exert its effect through i

148 Tranexamic acid is used in pre-hospital settings selecti

149 Tranexamic acid is widely available and used off-label i

150 fferent therapies among different countries, tranexamic acid is widely available, and is an effective

151 he most commonly used antifibrinolytic drug, tranexamic acid, is associated with an increased inciden

152 omly assigned within 8 h of injury to either tranexamic acid (loading dose 1 g over 10 min followed b

153 omly assigned within 8 h of injury to either tranexamic acid (loading dose 1 g over 10 min then infus

154 These findings suggest that tranexamic acid may be beneficial in various patient pop

155 Low-dose/enteral tranexamic acid may be effective in reducing hemorrhage;

156 Early administration of tranexamic acid may benefit patients with TBI.

157 Furthermore, there are concerns that tranexamic acid may have prothrombotic and proconvulsant

158 ng the administration of an adequate dose of tranexamic acid, may be important to improve maternal ou

159 an [SD], 26 [14.9]) groups compared with the tranexamic acid (mean [SD], 23.0 [19.2]) and no tranexam

160 They also had a lower dose of tranexamic acid (median dose 0.7 g versus 2 g, p = 0.035

161 vonorgestrel-IUS or usual medical treatment (tranexamic acid, mefenamic acid, combined estrogen-proge

162 Use of tranexamic acid might limit intracranial hematoma format

163 oxytocin monotherapy, 5849 patients received tranexamic acid monotherapy, 2964 patients received carb

164 ood cells and composed the following groups: tranexamic acid (n = 148), cryoprecipitate (n = 168), tr

165 h UGIB were randomly allocated to either the tranexamic acid (n=300) or the placebo group (n=300).

166 bserved in patients who received prehospital tranexamic acid (odds ratio [OR], 1.34; 95% CI, 1.16-1.5

167 Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in pa

168 We examined the effect of tranexamic acid on death due to bleeding according to ti

169 recorded strong evidence that the effect of tranexamic acid on death due to bleeding varied accordin

170 We recorded no evidence that the effect of tranexamic acid on death due to bleeding varied by systo

171 ssess the effects of early administration of tranexamic acid on death, vascular occlusive events, and

172 of early administration of a short course of tranexamic acid on death, vascular occlusive events, and

173 al (which originally evaluated the effect of tranexamic acid on mortality in trauma patients) was con

174 Treatment delay did not modify the effect of tranexamic acid on vascular occlusive events.

175 g to receipt of antifibrinolytic medication (tranexamic acid or aminocaproic acid) during the bleedin

176 ivery at 31 U.S. hospitals to receive either tranexamic acid or placebo after umbilical-cord clamping

177 r participants were randomized to either the tranexamic acid or placebo group.

178 plications to receive aspirin or placebo and tranexamic acid or placebo.

179 plications to receive aspirin or placebo and tranexamic acid or placebo.

180 Tranexamic acid or virally inactivated fresh frozen plas

181 severe isolated TBI who received prehospital tranexamic acid (OR, 4.49; 95% CI, 1.57-12.87; P = .005)

182 dysfunction in patients receiving aprotinin, tranexamic acid, or no antifibrinolytic treatment in the

183 to investigate whether the administration of tranexamic acid plus a prophylactic uterotonic agent dec

184 The most common combination therapy was tranexamic acid plus oxytocin (n=5331) followed by misop

185 ial evaluated extended-use (24 hr) high-dose tranexamic acid, prompting a reappraisal for tranexamic

186 Oxytocin plus tranexamic acid ranked as the most effective interventio

187 Oxytocin plus tranexamic acid ranked as the most effective interventio

188 rly, inhibiting endogenous fibrinolysis with tranexamic acid reduced retraction of fibrin polymers in

189 Tranexamic acid reduces bleeding and blood transfusion i

190 Tranexamic acid reduces the risk of bleeding among patie

191 Tranexamic acid reduces the risk of life-threatening pos

192 s about potential thromboembolic events with tranexamic acid remain.

193 ion of plasmin activation and/or activity by tranexamic acid reversed both the accelerated fibrin cle

194 Oxytocin plus tranexamic acid (RR 0.44 [95% CrI 0.33-0.58]) and carbet

195 Tranexamic acid safely reduced the risk of death in blee

196 On the basis of these results, tranexamic acid should be considered for use in bleeding

197 Tranexamic acid should be given as early as possible to

198 Tranexamic acid significantly decreased blood transfusio

199 Tranexamic acid significantly increased overall survival

200 Tranexamic acid significantly reduced all-cause mortalit

201 Tranexamic acid significantly reduced the risk of HE (ad

202 Tranexamic acid significantly reduces the failure to con

203 significantly inhibited by the lysine analog tranexamic acid suggesting that the protein-protein inte

204 ental biofilms and whether the lysine analog tranexamic acid (TA) inhibits LDC activity, biofilm accu

205 as significantly lower after two cycles with tranexamic acid than with recombinant VWF (146 [95% CI 1

206 log antifibrinolytics (aminocaproic acid and tranexamic acid), the serine protease inhibitor aprotini

207 ant VWF then tranexamic acid and 19 received tranexamic acid then recombinant VWF).

208 prevalence or number of remote DWIHLs after tranexamic acid treatment in acute ICH.

209 and received prophylactic uterotonic agents, tranexamic acid treatment resulted in a significantly lo

210 mucosal bleeding (four [6%] patients during tranexamic acid treatment vs zero during recombinant VWF

211 ted fibrinolysis is inhibited by addition of tranexamic acid (TXA) - a potent antifibrinolytic drug.

212 The antifibrinolytic drugs tranexamic acid (TXA) and epsilon-aminocaproic acid (EAC

213 zed trials have demonstrated the efficacy of tranexamic acid (TXA) in reducing blood loss and transfu

214 of the effectiveness of prophylactic use of tranexamic acid (TXA) in thrombocytopenia is lacking.

215 Tranexamic acid (TXA) is an efficient antifibrinolytic a

216 Tranexamic acid (TXA) is increasingly used to minimize p

217 Administration of tranexamic acid (TXA) to mouse plasma in vitro or health

218 isk of thromboembolic events associated with tranexamic acid (TXA) when administered intravenously, t

219 One exception is tranexamic acid (TXA), which, as a lysine mimetic, inhib

220 currently available antifibrinolytics, e.g., tranexamic acid (TXA, 1) and aprotinin, has been challen

221 prehospital TBI cohort from the Prehospital Tranexamic Acid Use for TBI clinical trial conducted acr

222 acid versus all other dosing strategies for tranexamic acid using fixed-effects models.

223 There was no evidence that the effect of tranexamic acid varied by the underlying risk of life-th

224 the data and explored whether the effect of tranexamic acid varied by the underlying risk of life-th

225 Studies were analyzed as high-dose IV tranexamic acid versus all other dosing strategies for t

226 sal treatment with bevacizumab vs estriol vs tranexamic acid vs placebo and epistaxis frequency.

227 TS: Multicenter randomized clinical trial of tranexamic acid vs placebo conducted from December 1, 20

228 Tranexamic acid was associated with a higher risk of pos

229 patients undergoing coronary-artery surgery, tranexamic acid was associated with a lower risk of blee

230 analysis demonstrated that administration of tranexamic acid was associated with a significant decrea

231 Neither aminocaproic acid nor tranexamic acid was associated with an increased risk of

232 Neither aminocaproic nor tranexamic acid was associated with increased risk of de

233 the resumption of menstruation, the dose of tranexamic acid was increased, and a subcutaneous inject

234 Tranexamic acid was not associated with favorable outcom

235 is and intraoperative factors such as use of tranexamic acid were collected.

236 arboprost, ergot alkaloids, misoprostol, and tranexamic acid were included in the final analysis.

237 Carbetocin alone and oxytocin plus tranexamic acid were superior to oxytocin monotherapy fo

238 ors, including epsilon-aminocaproic acid and tranexamic acid, were effective in treating and preventi

239 equally or more effective than aprotinin or tranexamic acid, which have been used as antifibrinolyti

240 re aprotinin, epsilon-aminocaproic acid, and tranexamic acid with placebo and head to head on 8 clini

241 o increase in vascular occlusive events with tranexamic acid, with no heterogeneity by site of bleedi